Thromboembolism

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

FRAGMINApproved

dalteparin sodium

Pfizer

injection1994

2M Part D

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

PfizerNEW YORK, NY

2 programs

Dalteparin sodiumPhase 41 trial

ApixabanPhase 1

Active Trials

NCT00655122Terminated8Est. Dec 2003

ViiV HealthcareNC - Durham

7 programs

ARIXTRA infusionPhase 3

FondaparinuxPhase 3

fondaparinux - UFH not indicatedPhase 3

fondaparinux sodiumPhase 3

+2 more programs

AstraZenecaCAMBRIDGE, United Kingdom

2 programs

EXANTAPhase 31 trial

BetrixabanPhase 21 trial

Active Trials

NCT00375609Completed215Est. Feb 2007

NCT00206089Terminated3,300Est. Aug 2006

SandozAustria - Kundl

1 program

CertoparinPhase 31 trial

Active Trials

NCT00451412Completed3,254Est. Jun 2009

Utah MedicalIreland - Dublin

1 program

PharmacogeneticPhase 31 trial

Active Trials

NCT01006733Completed1,598Est. Nov 2016

Leo PharmaDenmark - Ballerup

1 program

FragminPhase 2/31 trial

Active Trials

NCT00260988Completed29Est. Nov 2008

AstellasChina - Shenyang

2 programs

YM150Phase 21 trial

Active Trials

NCT00408239Completed367Est. Mar 2009

NCT00353678Completed1,141Est. Aug 2007

Boehringer IngelheimINGELHEIM, Germany

7 programs

PraxbindTMN/A1 trial

dabigatran etexilate low dosePHASE_21 trial

DabigatranPHASE_31 trial

Dabigatran etexilatePHASE_31 trial

WarfarinPHASE_31 trial

+2 more programs

Active Trials

NCT03359889Completed5Est. Jan 2020

NCT01505881Terminated158Est. Jun 2013

NCT00329238Completed2,867

+4 more trials

GSKLONDON, United Kingdom

6 programs

Special Drug Use Investigation for ARIXTRA® (Fondaparinux) InjectionN/A1 trial

fondaparinuxN/A1 trial

ARIXTRA infusionPHASE_31 trial

FondaparinuxPHASE_31 trial

+1 more programs

Active Trials

NCT01420809Completed1,280Est. Aug 2009

NCT01004939Completed120Est. Jul 2010

NCT00328939Completed240

+3 more trials

SanofiPARIS, France

2 programs

fondaparinux - UFH not indicatedPHASE_3

EnoxaparinPHASE_45 trials

Active Trials

NCT05819112Terminated14,799Est. Dec 2023

NCT00908960Completed70Est. Oct 2012

NCT00714597Terminated421Est. Mar 2009

+2 more trials

Bristol Myers SquibbPRINCETON, NJ

1 program

DVT After Cardiac ProcedureN/A1 trial

Active Trials

NCT03877770Completed82Est. Jul 2019

EppendorfGermany - Hamburg

1 program

Evaluation of Contrast Medium Enhanced Post-mortem CT in Virtual AutopsyN/A1 trial

Active Trials

NCT01541995Completed50

BayerLEVERKUSEN, Germany

1 program

No DrugN/A1 trial

Active Trials

NCT00911001Completed480Est. Mar 2009

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

SanofiEnoxaparin

PfizerDalteparin sodium

SanofiEnoxaparin

Boehringer IngelheimDabigatran etexilate

Utah MedicalPharmacogenetic

SanofiEnoxaparin

Boehringer IngelheimWarfarin

SanofiEnoxaparin

SandozCertoparin

SanofiEnoxaparin

Showing 15 of 41 trials with date data

Clinical Trials (41)

Total enrollment: 106,036 patients across 41 trials

NCT00518245 SanofiEnoxaparin

Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)

Start: Aug 2007Est. completion: Aug 200911 patients

Phase 4Terminated

NCT00444652 SanofiEnoxaparin

Thromboprophylaxis and Bariatric Surgery

Start: Nov 2006Est. completion: Dec 2012300 patients

Phase 4Unknown

NCT00347490 SanofiEnoxaparin

HENOX: Enoxaparine in Hemodialysis

Start: May 2006Est. completion: Jun 2007100 patients

Phase 4Completed

NCT00265993 SanofiEnoxaparin

Enoxaparin in Acute Venous Thromboembolic Disease

Start: Dec 2004Est. completion: Jan 2009251 patients

Phase 4Completed

NCT00655122 PfizerDalteparin sodium

Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study

Start: Apr 2003Est. completion: Dec 20038 patients

Phase 4Terminated

NCT00077818 SanofiEnoxaparin

Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)

Start: Jun 2002

Phase 4Completed

NCT00077753 SanofiEnoxaparin

EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization

Start: Feb 2002Est. completion: Feb 20074,726 patients

Phase 4Completed

NCT00289042 SanofiEnoxaparin

Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)

Start: Dec 1999Est. completion: Nov 2004200 patients

Phase 4Completed

NCT02913326 Boehringer IngelheimDabigatran etexilate

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Start: Dec 2016Est. completion: Jun 2018120 patients

Phase 3Completed

NCT01006733 Utah MedicalPharmacogenetic

Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

Start: Mar 2011Est. completion: Nov 20161,598 patients

Phase 3Completed

NCT00714597 SanofiEnoxaparin

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

Start: Jul 2008Est. completion: Mar 2009421 patients

Phase 3Terminated

NCT00680186 Boehringer IngelheimWarfarin

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

Start: Apr 20082,589 patients

Phase 3Completed

NCT00723216 SanofiEnoxaparin

Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery

Start: Mar 2007Est. completion: Dec 2007151 patients

Phase 3Completed

NCT00451412 SandozCertoparin

A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients

Start: Jan 2007Est. completion: Jun 20093,254 patients

Phase 3Completed

NCT00685958 SanofiEnoxaparin

Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery

Start: Jul 2006Est. completion: Mar 200754 patients

Phase 3Completed

NCT00349180 SanofiEnoxaparin

Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Start: Jun 2006156 patients

Phase 3Completed

NCT00329238 Boehringer IngelheimDabigatran

Secondary Prevention of Venous Thrombo Embolism (VTE).

Start: May 20062,867 patients

Phase 3Completed

NCT00320424 GSKFondaparinux

Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

Start: Feb 2006Est. completion: Oct 200648 patients

Phase 3Completed

NCT00291330 Boehringer Ingelheimdabigatran etexilate 150 mg

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

Start: Feb 20062,564 patients

Phase 3Completed

NCT00206089 AstraZenecaEXANTA

Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events

Start: Sep 2005Est. completion: Aug 20063,300 patients

Phase 3Terminated

NCT00168818 Boehringer Ingelheimdabigatran etexilate

Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery

Start: Nov 20043,494 patients

Phase 3Completed

NCT00328939 GSKARIXTRA infusion

ARIXTRA Local Study For Registration In China.

Start: May 2004240 patients

Phase 3Completed

NCT00064428 GSKfondaparinux - UFH not indicated

OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

Start: Aug 2003Est. completion: Feb 200612,092 patients

Phase 3Completed

NCT00139815 GSKFondaparinux

Michelangelo - Oasis 5

Start: Apr 2003Est. completion: Dec 200520,078 patients

Phase 3Completed

NCT00077792 SanofiEnoxaparin

Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)

Start: Oct 2002Est. completion: Dec 200620,506 patients

Phase 3Completed

NCT00043784 SanofiEnoxaparin

SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

Start: Aug 20018,000 patients

Phase 3Completed

NCT00260988 Leo PharmaFragmin

A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery

Start: Oct 2003Est. completion: Nov 200829 patients

Phase 2/3Completed

NCT01505881 Boehringer Ingelheimdabigatran etexilate low dose

Follow on Study From RE-ALIGN

Start: Dec 2011Est. completion: Jun 2013158 patients

Phase 2Terminated

NCT00908960 SanofiEnoxaparin

Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles

Start: May 2009Est. completion: Oct 201270 patients

Phase 2Completed

NCT00408239 AstellasYM150

Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement

Start: Dec 2006Est. completion: Mar 2009367 patients

Phase 2Completed

NCT00353678 AstellasYM150

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

Start: Jun 2006Est. completion: Aug 20071,141 patients

Phase 2Completed

NCT00375609 AstraZenecaBetrixaban

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

Start: May 2006Est. completion: Feb 2007215 patients

Phase 2Completed

NCT00622115 SanofiEnoxaparin

Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)

Start: Jul 2007Est. completion: Nov 200772 patients

Phase 1Completed

NCT05819112 SanofiEnoxaparin

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

Start: Apr 2023Est. completion: Dec 202314,799 patients

N/ATerminated

NCT03359889 Boehringer IngelheimPraxbindTM

PraxbindTM India PMS Program

Start: Dec 2018Est. completion: Jan 20205 patients

N/ACompleted

NCT03877770 Bristol Myers SquibbDVT After Cardiac Procedure

DVT After Cardiac Procedure

Start: Oct 2017Est. completion: Jul 201982 patients

N/ACompleted

NCT01541995 EppendorfEvaluation of Contrast Medium Enhanced Post-mortem CT in Virtual Autopsy

Evaluation of Contrast Medium Enhanced Post-mortem CT in Virtual Autopsy

Start: Apr 201250 patients

N/ACompleted

NCT01004939 GSKfondaparinux

Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism

Start: Mar 2010Est. completion: Jul 2010120 patients

N/ACompleted

NCT00911001 BayerNo Drug

SALTO - Epidemiological Study on Compliance and Treatment Satisfaction

Start: Nov 2008Est. completion: Mar 2009480 patients

N/ACompleted

NCT01420809 GSKSpecial Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection

Start: Sep 2007Est. completion: Aug 20091,280 patients

N/ACompleted

NCT00413374 SanofiEnoxaparin

Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism

Start: May 2006Est. completion: Dec 200840 patients

N/ACompleted

Related Jobs

Therapy Development Specialist - South Florida

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

8 late-stage (Phase 3) programs, potential near-term approvals

13 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.